Co-treatment with Vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer

ALK5 inhibitor suppressed radiation induced metastasis

Authors

  • Yhunyhong Sheen Ewha Womans University
  • Ilyoung Cho College of Pharmacy, Ewha Womans University
  • Jiwon Choi College of Pharmacy, Ewha Womans University
  • Jiyoung Park College of Pharmacy, Ewha Womans University

Abstract

Background: Acquired metastasis and invasion of cancer cells during radiotherapy are in part due to induction of epithelial-to-mesenchymal transition (EMT) and cancer stem cell (CSC) properties, which are mediated by TGF-β sign-aling. Here we evaluated the anti-metastatic therapeutic potential of vactosertib, an orally bioavailable TGF-β type Ireceptor (activin receptor-like kinase 5, ALK5) inhibitor, via suppression of radiation-induced EMT and CSC properties, oxidative stress generation, and breast to lung metastasis in a breast cancer mouse model and breast cancer cell lines.


Materials and methods: Co-treatment of vactosertib with radiation was investigated in the 4T1-Luc allografted BALB/c syngeneic mouse model and in 4T1-Luc and MDA-MB-231 cells. The anti-metastatic therapeutic potential of vactosertib in breast cancer was investigated using fluorescence immunohistochemistry, real-time quantitative reverse transcription-polymerase chain reaction, western blotting, wound healing assay, mammosphere formation assay, and lung metastasis analysis in vitro and in vivo.


Results: Radiation induced TGF-β signaling, EMT markers (Vimentin, Fibronectin, Snail, Slug, Twist, and N-cadherin), CSC properties (expression of pluripotent stem cell regulators, mammosphere forming ability), reactive oxygen species markers (NOX4, 4-HNE), and motility of breast cancer cells in vitro and in vivo. Vactosertib attenuated the radiation-induced EMT and CSC properties by inhibiting ROS stress in breast cancer. Moreover, vactosertib combined with radiation showed a significant anti-metastatic effect with suppression of breast to lung metastasis in vivo.


Conclusions: These results indicate that inhibition of TGF-β signaling with vactosertib in breast cancer patients under-going radiotherapy would be an attractive strategy for the prevention of cancer metastasis and recurrence.

Author Biographies

  • Yhunyhong Sheen, Ewha Womans University

    Ph.D, Corresponding Author

  • Ilyoung Cho, College of Pharmacy, Ewha Womans University

    Ph.D, co-first author

  • Jiwon Choi, College of Pharmacy, Ewha Womans University

    B.S., co-first author

  • Jiyoung Park, College of Pharmacy, Ewha Womans University

    B.S.

Downloads

Additional Files

Published

2022-07-03

Issue

Section

Experimental oncology

How to Cite

Co-treatment with Vactosertib, a novel, orally bioavailable activin receptor-like kinase 5 inhibitor, suppresses radiotherapy-induced epithelial-to-mesenchymal transition, cancer cell stemness, and lung metastasis of breast cancer: ALK5 inhibitor suppressed radiation induced metastasis. (2022). Radiology and Oncology, 56(2), 185-197. https://www.ojstest.computing.si/index.php/ro/article/view/3779